Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Venclexta (Venetoclax) for the Treatment of Chronic Lymphocytic Leukaemia

Drug (Brand/Generic)

Venclexta ( Venetoclax)

Therapy Class

B-cell lymphoma-2 (BCL-2) inhibitor

Current Indication

Chronic lymphocytic leukaemia

Market Sector

Oncology

Development Status

Approved in the US

Developer

AbbVie
Expand

Go Top